Neurotransmitter receptor and time dependence of the synaptic plasticity disrupting actions of Alzheimer's disease Aβ in vivo

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 369, Issue 1633, 2014, Pages

  Klyubin, Igor ^a   Ondrejcak, Tomas ^a   Hayes, Jennifer ^a   Cullen, William K ^a   Mably, Alexandra J ^b   Walsh, Dominic M ^b   Rowan, Michael J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Amyloid protein; Long term potentiation; Muscarinic receptor; Nicotinic receptor; NMDA receptor

Indexed keywords

BRAIN; ENZYME ACTIVITY; INHIBITION; NEUROLOGY; PROTEIN; TIME DEPENDENT BEHAVIOR;

RATTUS;

ACETYLCHOLINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); MUSCARINIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINIC RECEPTOR; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; AMYLOID-Β PROTEIN; ANALYSIS OF VARIANCE; ANIMAL; ARTICLE; BRAIN LEVEL; DRUG EFFECT; EXCITATORY POSTSYNAPTIC POTENTIAL; EXTRACELLULAR FLUID; HIPPOCAMPUS; HUMAN; LONG TERM POTENTIATION; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; SYNAPSE; WISTAR RAT;

ALZHEIMER'S DISEASE; AMYLOID-Β PROTEIN; LONG-TERM POTENTIATION; MUSCARINIC RECEPTOR; NICOTINIC RECEPTOR; NMDA RECEPTOR;

ACETYLCHOLINE; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANIMALS; BRAIN CHEMISTRY; EXCITATORY POSTSYNAPTIC POTENTIALS; EXTRACELLULAR FLUID; HIPPOCAMPUS; HUMANS; LONG-TERM POTENTIATION; MALE; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, NICOTINIC; SYNAPSES;

EID: 84888779957     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2013.0147     Document Type: Article

References (59)

1. Corbett A, Smith J, Ballard C. 2012 New and emerging treatments for Alzheimer's disease. Expert Rev. Neurother. 12, 535-543. (doi:10.1586/ern.12.43)
2. Jack Jr CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH. 2011 Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 257-262. (doi:10.1016/j.jalz.2011.03.004)
3. Schwarz S, Froelich L, Burns A. 2012 Pharmacological treatment of dementia. Curr. Opin Psychiatry 25, 542-550. (doi:10.1097/YCO. 0b013e328358e4f2)
4. Selkoe DJ, Mandelkow E, Holtzman DM. (eds) 2012 The biology of Alzheimer's disease. New York, NY: Cold Spring Harbor Laboratory Press.
5. Benilova I, Karran E, De Strooper B. 2012 The toxic Ab oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 15, 349-357. (doi:10.1038/nn.3028)
6. Larson ME, Lesne SE. 2012 Soluble Ab oligomer production and toxicity. J. Neurochem. 120(Suppl. 1), 125-139. (doi:10.1111/j.1471-4159.2011.07478.x)
7. Hu NW, Ondrejcak T, Rowan MJ. 2012 Glutamate receptors in preclinical research on Alzheimer's disease: update on recent advances. Pharmacol. Biochem. Behav. 100, 855-862. (doi:10.1016/j.pbb. 2011.04.013)
8. Ondrejcak T, Klyubin I, Hu NW, Barry AE, Cullen WK, Rowan MJ. 2010 Alzheimer's disease amyloid b-protein and synaptic function. Neuromolecular Med. 12, 13-26. (doi:10.1007/s12017-009-8091-0)
9. Palop JJ, Mucke L. 2010 Amyloid-b-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 13, 812-818. (doi:10.1038/nn.2583)
10. Wang Q, Rowan MJ, Anwyl R. 2004 β-amyloidmediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J. Neurosci. 24, 6049-6056. (doi:10.1523/JNEUROSCI.0233-04.2004)
11. Hu NW, Klyubin I, Anwyl R, Rowan MJ. 2009 GluN2B subunit-containing NMDA receptor antagonists prevent Ab-mediated synaptic plasticity disruption in vivo. Proc. Natl Acad. Sci. USA 106, 20 504-20 509. (doi:10.1073/pnas.0908083106)
12. Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D. 2009 Soluble oligomers of amyloid b protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62, 788-801. (doi:10.1016/j.neuron.2009.05.012)
13. Rammes G, Hasenjager A, Sroka-Saidi K, Deussing JM, Parsons CG. 2011 Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of b-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. Neuropharmacology 60, 982-990. (doi:10.1016/j.neuropharm. 2011.01.051)
14. Ronicke R, Mikhaylova M, Ronicke S, Meinhardt J, Schroder UH, Fandrich M, Reiser G, Kreutz MR, Reymann KG. 2011 Early neuronal dysfunction by amyloid b oligomers depends on activation of NR2B-containing NMDA receptors. Neurobiol. Aging 32, 2219-2228. (doi:10.1016/j.neurobiolaging. 2010.01.011)
15. Shankar GM et al. 2008 Amyloid-b protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842. (doi:10.1038/nm1782)
16. Hu NW, Smith IM, Walsh DM, Rowan MJ. 2008 Soluble amyloid-b peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo. Brain 131, 2414-2424. (doi:10.1093/brain/awn174)
17. Ryan BK, Vollmayr B, Klyubin I, Gass P, Rowan MJ. 2010 Persistent inhibition of hippocampal longterm potentiation in vivo by learned helplessness stress. Hippocampus 20, 758-767. (doi:10.1002/ hipo.20677)
18. Randall AD, Tsien RW. 1997 Contrasting biophysical and pharmacological properties of T-type and Rtype calcium channels. Neuropharmacology 36, 879-893. (doi:10.1016/S0028-3908(97)00086-5)
19. 2+channels. Trends Pharmacol. Sci. 18, 37-42. (doi:10.1016/S0165-6147(96)01021-8)
20. 2+channels in the potentiation of synaptic and visual responses during the critical period in rat visual cortex. Eur. J. Neurosci. 28, 730-743. (doi:10.1111/j.1460-9568.2008.06384.x)
21. Grover LM, Teyler TJ. 1990 Two components of long-term potentiation induced by different patterns of afferent activation. Nature 347, 477-479. (doi:10.1038/347477a0)
22. Randall AD, Witton J, Booth C, Hynes-Allen A, Brown JT. 2010 The functional neurophysiology of the amyloid precursor protein (APP) processing pathway. Neuropharmacology 59, 243-267. (doi:10.1016/j.neuropharm.2010.02.011)
23. Yu JT, Chang RC, Tan L. 2009 Calcium dysregulation in Alzheimer's disease: from mechanisms to therapeutic opportunities. Progr. Neurobiol. 89, 240-255. (doi:10.1016/j.pneurobio.2009.07.009)
24. Li L, Tsai HJ, Li L, Wang XM. 2010 Icariin inhibits the increased inward calcium currents induced by amyloid-b(25-35) peptide in CA1 pyramidal neurons of neonatal rat hippocampal slice. Am. J. Chinese Med. 38, 113-125. (doi:10.1142/ S0192415X10007701)
25. Rovira C, Arbez N, Mariani J. 2002 Ab(25-35) and Ab(1-40) act on different calcium channels in CA1 hippocampal neurons. Biochem. Biophys Res Commun. 296, 1317-1321. (doi:10.1016/S0006-291X(02)02072-7)
26. Nomura I, Kato N, Kita T, Takechi H. 2005 Mechanism of impairment of long-term potentiation by amyloid b is independent of NMDA receptors or voltage-dependent calcium channels in hippocampal CA1 pyramidal neurons. Neurosci. Lett. 391, 1-6. (doi:10.1016/j.neulet.2005.08.024)
27. Takahashi H, Magee JC. 2009 Pathway interactions and synaptic plasticity in the dendritic tuft regions of CA1 pyramidal neurons. Neuron 62, 102-111. (doi:10.1016/j.neuron.2009.03.007)
28. Yasuda R, Sabatini BL, Svoboda K. 2003 Plasticity of calcium channels in dendritic spines. Nat. Neurosci. 6, 948-955. (doi:10.1038/nn1112)
29. Gu Z, Yakel JL. 2011 Timing-dependent septal cholinergic induction of dynamic hippocampal synaptic plasticity. Neuron 71, 155-165. (doi:10. 1016/j.neuron.2011.04.026)
30. Mann EO, Greenfield SA. 2003 Novel modulatory mechanisms revealed by the sustained application of nicotine in the guinea-pig hippocampus in vitro. J. Physiol. 551, 539-550. (doi:10.1113/jphysiol. 2003.045492)
31. Welsby P, Rowan M, Anwyl R. 2006 Nicotinic receptor-mediated enhancement of long-term potentiation involves activation of metabotropic glutamate receptors and ryanodine-sensitive calcium stores in the dentate gyrus. Eur. J. Neurosci. 24, 3109-3118. (doi:10.1111/j.1460-9568.2006. 05187.x)
32. Welsby PJ, Rowan MJ, Anwyl R. 2009 Intracellular mechanisms underlying the nicotinic enhancement of LTP in the rat dentate gyrus. Eur. J. Neurosci. 29, 65-75. (doi:10.1111/j.1460-9568.2008.06562.x)
33. Welsby PJ, Rowan MJ, Anwyl R. 2007 β-Amyloid blocks high frequency stimulation induced LTP but not nicotine enhanced LTP. Neuropharmacology 53, 188-195. (doi:10.1016/j.neuropharm.2007.05.013)
34. Hayes J, Li S, Anwyl R, Rowan MJ. 2008 A role for protein kinase A and protein kinase M z in muscarinic acetylcholine receptor-initiated persistent synaptic enhancement in rat hippocampus in vivo. Neuroscience 151, 604-612. (doi:10.1016/j. neuroscience.2007.10.016)
35. Li S, Cullen WK, Anwyl R, Rowan MJ. 2007 Muscarinic acetylcholine receptor-dependent induction of persistent synaptic enhancement in rat hippocampus in vivo. Neuroscience 144, 754-761. (doi:10.1016/j.neuroscience.2006.10.001)
36. Kelly JF, Furukawa K, Barger SW, Rengen MR, Mark RJ, Blanc EM, Roth GS, Mattson MP. 1996 Amyloid b-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons. Proc. Natl Acad. Sci. USA 93, 6753-6758. (doi:10. 1073/pnas.93.13.6753)
37. Vitolo OV, Sant'Angelo A, Costanzo V, Battaglia F, Arancio O, Shelanski M. 2002 Amyloid b-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc. Natl Acad. Sci. USA 99, 13 217-13 221. (doi:10.1073/pnas.172504199)
38. Li S, Jin M, Zhang D, Yang T, Koeglsperger T, Fu H, Selkoe D. 2013 Environmental novelty activates b2-adrenergic signaling to prevent the impairment of hippocampal LTP by Ab oligomers. Neuron 77, 929-941. (doi:10.1016/j.neuron.2012.12.040)
39. Wang QW, Rowan MJ, Anwyl R. 2009 Inhibition of LTP by b-amyloid is prevented by activation of b2 adrenoceptors and stimulation of the cAMP/PKA signalling pathway. Neurobiol. Aging 30, 1608-1613. (doi:10.1016/j.neurobiolaging.2007.12.004)
40. Fisher A. 2012 Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease. J. Neurochem. 120(Suppl. 1), 22-33. (doi:10.1111/j.1471-4159. 2011.07507.x)
41. Cullen WK, Anwyl R, Rowan MJ. 1997 β-amyloid produces a selective block of late-phase long-term potentiation in rat hippocampus in vivo. Br. J. Pharmacol. 122, 330-334. (doi:10.1038/sj. bjp.0701393)
42. Hunter BE, de Fiebre CM, Papke RL, Kem WR, Meyer EM. 1994 A novel nicotinic agonist facilitates induction of long-term potentiation in the rat hippocampus. Neurosci. Lett. 168, 130-134. (doi:10.1016/0304-3940(94)90433-2)
43. Chen L, Yamada K, Nabeshima T, Sokabe M. 2006 α7 Nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in b-amyloid infused rats. Neuropharmacology 50, 254-268. (doi:10.1016/j.neuropharm.2005.09.018)
44. Castro NG, Albuquerque EX. 1995 α-Bungarotoxinsensitive hippocampal nicotinic receptor channel has a high calcium permeability. Biophys. J. 68, 516-524. (doi:10.1016/S0006-3495(95)80213-4)
45. Buccafusco JJ, Letchworth SR, Bencherif M, Lippiello PM. 2005 Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance. Trends Pharmacol. Sci. 26, 352-360. (doi:10.1016/j. tips.2005.05.007)
46. Dineley KT, Bell KA, Bui D, Sweatt JD. 2002 α-Amyloid peptide activates a7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J. Biol. Chem. 277, 25 056-25 061. (doi:10.1074/jbc.M200066200)
47. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. 2000 β-Amyloid(1-42) binds to a7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J. Biol. Chem. 275, 5626-5632. (doi:10.1074/jbc. 275.8.5626)
48. Ondrejcak T, Wang Q, Kew JN, Virley DJ, Upton N, Anwyl R, Rowan MJ. 2012 Activation of a7 nicotinic acetylcholine receptors persistently enhances hippocampal synaptic transmission and prevents Ass-mediated inhibition of LTP in the rat hippocampus. Eur. J. Pharmacol. 677, 63-70. (doi:10.1016/j.ejphar.2011.12.008)
49. Meilandt WJ, Cisse M, Ho K, Wu T, Esposito LA, Scearce-Levie K, Cheng IH, Yu G-Q, Mucke L. 2009 Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Ab oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J. Neurosci. 29, 1977-1986. (doi:10.1523/ JNEUROSCI.2984-08.2009)
50. Riedel G, Seidenbecher T, Reymann KG. 1994 LTP in hippocampal CA1 of urethane-narcotized rats requires stronger tetanization parameters. Physiol. Behav. 55, 1141-1146. (doi:10.1016/0031-9384(94)90401-4)
51. Mc Donald JM, Savva GM, Brayne C, Welzel AT, Forster G, Shankar GM, Selkoe DJ, Ince PG, Walsh DM. 2010 The presence of sodium dodecyl sulphate-stable Ab dimers is strongly associated with Alzheimer-type dementia. Brain 133, 1328-1341. (doi:10.1093/brain/awq065)
52. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. 2011 Soluble Ab oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2Bcontaining NMDA receptors. J. Neurosci. 31, 6627-6638. (doi:10.1523/JNEUROSCI.0203-11.2011)
53. Barry AE, Klyubin I, Mc Donald JM, Mably AJ, Farrell MA, Scott M, Walsh DM, Rowan MJ. 2011 Alzheimer's disease brain-derived amyloid-b-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J. Neurosci. 31, 7259-7263. (doi:10.1523/JNEUROSCI.6500-10.2011)
54. Freir DB et al. 2011 Interaction between prion protein and toxic Ab assemblies can be therapeutically targeted at multiple sites. Nat. Commun. 2, 336. (doi:10.1038/ncomms1341)
55. Borlikova GG, Trejo M, Mably AJ, Mc Donald JM, Sala Frigerio C, Regan CM, Murphy KJ, Masliah E, Walsh DM. 2013 Alzheimer brain-derived amyloid b-protein impairs synaptic remodeling and memory consolidation. Neurobiol. Aging 34, 1315-1327. (doi:10.1016/j.neurobiolaging.2012.10.028)
56. Kane MD et al. 2000 Evidence for seeding of bamyloid by intracerebral infusion of Alzheimer brain extracts in b-amyloid precursor protein-transgenic mice. J. Neurosci. 20, 3606-3611.
57. Langer F, Eisele YS, Fritschi SK, Staufenbiel M, Walker LC, Jucker M. 2011 Soluble Ab seeds are potent inducers of cerebral b-amyloid deposition. J. Neurosci. 31, 14 488-14 495. (doi:10.1523/ JNEUROSCI.3088-11.2011)
58. Cullen WK, Suh YH, Anwyl R, Rowan MJ. 1997 Block of LTP in rat hippocampus in vivo by b-amyloid precursor protein fragments. Neuroreport 8, 3213-3217. (doi:10.1097/00001756-199710200-00006)
59. Klyubin I, Walsh DM, Cullen WK, Fadeeva JV, Anwyl R, Selkoe DJ, Rowan MJ. 2004 Soluble Arctic amyloid b protein inhibits hippocampal long-term potentiation in vivo. Eur. J. Neurosci. 19, 2839-2846. (doi:10.1111/j.1460-9568.2004.03389.x)